High-Dose Verapamil in Episodic and Chronic Cluster Headaches and Cardiac Adverse Events: Is It as Safe as We Think?

Olesen J. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. 2nd Edition. Cephalalgia Int J Headache. 2004;24:1–160.

May A, Leone M, Afra J, Linde M, Sándor PS, Evers S, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol Off J Eur Fed Neurol Soc. 2006;13:1066–77.

Bussone G, Leone M, Peccarisi C, Micieli G, Granella F, Magri M, et al. Double blind comparison of lithium and verapamil in cluster headache prophylaxis. Headache. 1990;30:411–7.

Leone M, D’Amico D, Frediani F, Moschiano F, Grazzi L, Attanasio A, et al. Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. Neurology. 2000;54:1382–5.

ISOPTINE® 120 mg. Résumé des caractéristiques du produit [Internet]. Base Données Publiques Médicam. Ministère Aff. Soc. Santé Fr. [cited 2014 Dec 12]. Available from: http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=66814925&typedoc=R#RcpPosoAdmin .

Donnet A, Demarquay G, Ducros A, Geraud G, Giraud P, Guegan-Massardier E, et al. French guidelines for diagnosis and treatment of cluster headache (French Headache Society). Rev Neurol (Paris). 2014;170:653–70.

Leenhardt A, Glaser E, Burguera M, Nürnberg M, Maison-Blanche P, Coumel P. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation. 1994;89:206–15.

Gabai IJ, Spierings EL. Prophylactic treatment of cluster headache with verapamil. Headache. 1989;29:167–8.

Matharu MS, Boes CJ, Goadsby PJ. Management of trigeminal autonomic cephalgias and hemicrania continua. Drugs. 2003;63:1637–77.

Lanteri-Minet M, Silhol F, Piano V, Donnet A. Cardiac safety in cluster headache patients using the very high dose of verapamil (≥720 mg/day). J Headache Pain. 2011;12:173–6.

Murphy KM, Gould RJ, Largent BL, Snyder SH. A unitary mechanism of calcium antagonist drug action. Proc Natl Acad Sci. 1983;80:860–4.

Thayer SA, Welcome M, Chhabra A, Fairhurst AS. Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985;34:175–80.

Ohashi M, Kanai R, Takayanagi I. Do D 600 and diltiazem interact with serotonin receptors in rabbit vascular tissues? J Pharmacol Exp Ther. 1985;233:830–5.

Maisel AS, Motulsky HJ, Insel PA. Hypotension after quinidine plus verapamil. Possible additive competition at alpha-adrenergic receptors. N Engl J Med. 1985;312:167–70.

Rezvani AH, Beleslin DB, Myers RD. Neuroanatomical mapping of hypothalamic regions mediating verapamil hyper- and hypothermia in the cat. Brain Res Bull. 1986;17:249–54.

Kavaliers M. Calcium channel blockers inhibit the antagonistic effects of Phe-Met-Arg-Phe-amide (FMRFamide) on morphine- and stress-induced analgesia in mice. Brain Res. 1987;415:380–4.

Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A. Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit Care Lond Engl. 2012;16:R136.

Cercle de Reflexion sur l’Imputabilite, Arimone Y, Bidault I, Dutertre J-P, Gérardin M, Guy C, et al. Update of the French drug reaction assessment method. Thérapie. 2011;66:517–25.

Goadsby PJ. Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. Lancet Neurol. 2002;1:251–7.

Meyer JS, Hardenberg J. Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headaches. Headache. 1983;23:266–77.

Meyer JS, Nance M, Walker M, Zetusky WJ, Dowell RE. Migraine and cluster headache treatment with calcium antagonists supports a vascular pathogenesis. Headache. 1985;25:358–67.

Cohen AS, Matharu MS, Goadsby PJ. Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology. 2007;69:668–75.

Becker WJ. Cluster headache: conventional pharmacological management. Headache. 2013;53:1191–6.

Leroux E, Valade D, Taifas I, Vicaut E, Chagnon M, Roos C, et al. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10:891–7.

Guize L, Piot O, Lavergne T, Le Heuzey J-Y. Cardiac arrhythmias in the elderly. Bull Académie Natl Médecine. 2006;190:827–41 (discussion 873–6).

McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.

Ashraf M, Chaudhary K, Nelson J, Thompson W. Massive overdose of sustained-release verapamil: a case report and review of literature. Am J Med Sci. 1995;310:258–63.

Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993;348:332–7.

Woodland C, Koren G, Wainer IW, Batist G, Ito S. Verapamil metabolites: potential P-glycoprotein-mediated multidrug resistance reversal agents. Can J Physiol Pharmacol. 2003;81:800–5.

Kaeser YA, Brunner F, Drewe J, Haefeli WE. Severe hypotension and bradycardia associated with verapamil and clarithromycin. Am J Health Syst Pharm. 1998;55:2417–8.

Reed M, Wall GC, Shah NP, Heun JM, Hicklin GA. Verapamil toxicity resulting from a probable interaction with telithromycin. Ann Pharmacother. 2005;39:357–60.

Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. CMAJ. 2011;183:303–7.

Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther. 2000;67:498–503.

Villikka K, Varis T, Backman JT, Neuvonen PJ, Kivistö KT. Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo. Eur J Clin Pharmacol. 2001;57:457–60.

Lin JH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev. 2003;55:53–81.

Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther. 2006;79:218–30.

Karssen AM, Meijer OC, van der Sandt ICJ, De Boer AG, De Lange ECM, De Kloet ER. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol. 2002;175:251–60.

TERALITHE® 250 mg. Résumé des caractéristiques du produit [Internet]. Base Données Publiques Médicam. Ministère Aff. Soc. Santé Fr. [cited 2014 Dec 12]. Available from: http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=62124478&typedoc=R .

Commission d’évaluation initiale du rapport bénéfice risque des produits de santé. ANSM: Agence nationale de sécurité du médicament et des produits de santé [Internet]. [cited 2014 Dec 16]. Available from: http://ansm.sante.fr/L-ANSM2/Commissions-consultatives/Commission-d-evaluation-initiale-du-rapport-benefice-risque-des-produits-de-sante/(offset)/1 .